Stay Curious. Stay Connected.
MailNewsletters♡Donate Now
Sign up
*Password must be at least 8 characters and contain one uppercase letter, one lowercase letter, one number and one symbol.
Already have an account?
By submitting, you consent that you are at least 18 years of age and to receive information about MPR's or APMG entities' programs and offerings. The personally identifying information you provide will not be sold, shared, or used for purposes other than to communicate with you about MPR, APMG entities, and its sponsors. You may opt-out at any time clicking the unsubscribe link at the bottom of any email communication. View our Privacy Policy.
Sign in to your profile
Forgot Password?
New to MPR News?
Welcome back
to news
for you
Reset Password

Enter the username on file and we'll send you a code to reset your password.

Still require assistance or not sure what your User Name is?
Welcome back
to news
for you
Email Verification

A verification code has been emailed to

Still awaiting the code?
Reuters

Medical device maker Stryker Corp has made a takeover approach to rival Boston Scientific

Go Deeper.

Create an account or log in to save stories.

Log inCreate a free Account

Like this?

Thanks for liking this story! We have added it to a list of your favorite stories.

Show me!

Medical device maker Stryker Corp has made a takeover approach to rival Boston Scientific Corp, the Wall Street Journal reported on Monday, a combination that would give Stryker a strong position in stroke-preventing heart products.

Boston Scientific's share price closed up 7.4 percent at $34.32 Monday. Stryker's fell 5.1 percent to $169.78.

A deal would create a combined company with a market value of more than $110 billion and a wide breadth of product offerings from cardiology and orthopedics to surgical supplies and neuroscience at a time when leaders in the sector feel the need to get bigger to be able to offer hospitals and other customers a one-stop shopping experience.

It is not clear whether Boston Scientific is open to a potential acquisition by Stryker, the Journal reported, citing people familiar with the matter.

Representatives of both Stryker and Boston Scientific declined to comment on the report. But the two have done business before. Stryker bought Boston Scientific's neurovascular unit in 2010 for $1.5 billion.

"If this news is accurate, it would create a roughly $24 billion medtech company, which would place it behind only Medtronic and Johnson & Johnson in total device revenue," Wells Fargo Securities analyst Lawrence Biegelsen said in a research note.

He added that the combination would be one of broader scale with limited product overlap.

If the deal were to happen, Stryker would gain Boston Scientific's line of heart devices, such as stents to prop open clogged arteries, defibrillators to correct dangerously out of whack heart rhythms and its Watchman device to prevent blood clots from traveling around the heart. All of those devices reduce the risk of stroke.

The company has numerous other product lines that could enhance Stryker's offerings, including in orthopedic surgery and neurological surgery products.

Boston Scientific lags behind Edwards Lifesciences Corp and Medtronic Plc in the fast-growing heart valve replacement market. It has pinned its hopes on an improved version of its Lotus replacement valve, set for launch in 2019 after withdrawal of an earlier version from Europe last year.

Stryker already has a leading position in orthopedics, such as spinal surgery devices and hip and knee replacements, as well as medical and surgical equipment.

There has been a slow stream of large consolidation deals in the medical device sector in recent years.

"For all the medtech companies, in order to remain and to become a more valuable supplier to their hospital customers, it is really more and more important to be able to offer ... a much more comprehensive product portfolio that sells into all different parts of the hospital under different specialties," Morningstar analyst Debbie Wang said.